WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) recently granted stock options covering 685,718 shares to five newly hired non-executive employees under its 2026 Inducement Equity Plan, the company announced.
The awards, effective March 31, were approved by the company’s board compensation committee as an inducement for employment under Nasdaq listing rules.
The options carry an exercise price of $1.68 per share, equal to the company’s closing stock price on the grant date, and have a 10-year term.
Twenty-five percent of the options will vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following three years.
The grants are subject to the terms of the company’s inducement plan approved in March 2026 and individual award agreements.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.